Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system.
Bryant AK, Lewy JR, Bressler RD, Chopra Z, Gyori DJ, Bazzell BG, Moeller JA, Jacobson SI, Fendrick AM, Kerr EA, Ramnath N, Green MD, Hofer TP, Vaishnav P, Strohbehn GW.
Bryant AK, et al. Among authors: strohbehn gw.
Lancet Oncol. 2024 Jun;25(6):802-810. doi: 10.1016/S1470-2045(24)00200-6.
Lancet Oncol. 2024.
PMID: 38821085